January 18, 2022

Austin, TX – CReDO Science and EndoCanna Health are delighted to partner to provide a screening test for cannabinoid hyperemesis syndrome (CHS). CReDO Science CEO and the inventor of the screening technology, Ethan Russo, M.D. says, “CHS previously has been an enigmatic disorder that has been a tremendous burden of abdominal pain, nausea, and vomiting for its patients. Simultaneously, it has been a diagnostic dilemma for hospital emergency departments that attempt to decipher its diagnosis with various expensive and sometimes invasive tests that usually provide little insight to the problem.”

Dr. Russo has been seeking to understand the origins of CHS for years. In 2019, his company approached Len May, the CEO of EndoCanna Health, where Dr. Russo serves as a Scientific Advisory Board member, to find that they, too, cared about solving the mystery of CHS. Dr. Russo designed and oversaw a research study executed and analyzed by EndoCanna Health which led to the discovery of five genes that appear to occur in CHS patients at significantly higher rates than the general population.  Where an individual has two or more of the five genes, it is an indication they are at much greater risk for CHS, which is triggered by chronic consumption of high THC cannabis and cannabis products.

Mr. May explains, “With the advent of this new technology, an inexpensive, simple mouth swab may provide insight to patients, their families, and physicians as to the source of the problem, and its impact.” Dr. Russo explains further the importance of this screening tool, “Our research has provided the understanding of CHS as a genetic susceptibility, and one that has implications for risks for other disorders including alcoholism, addiction to other substances, and risks for future development of heart disease and dementia, among others.”

We believe this technology will have important public health implications and offer significant savings in cost expenditures for unnecessary diagnostic tests, which patients surveyed have reported reaching $90,000-100,000. Highlighting the party’s collective intent to serve patients, Mr. May points out, “Through our HIPPA compliant process, we are able to provide the privacy patients desire with important data physicians need to aid in diagnosis and to educate patients about recovery.”

It is estimated approximately 50,000 people a year develop CHS.  That figure is expected to increase significantly as cannabis legalization occurs across more jurisdictions globally.  Some estimates for CHS prevalence have been as high as 2 million patients in the U.S., but no one knows.

Tests can be ordered by patients and physicians through the sales portal  https://shop.endodna.com/products/chs-dna-susceptibility-test. Additional information about CHS is available at www.what-is-chs.com.

CReDO Science LLC is a biopharma holding company that exists to solve problems of the human/animal ECS including developing optimized formulations from the Cannabis plant for better living. Learn more at www.credo-science.com.

Endocanna Health is the industry leader in endocannabinoid system genomic testing and the manufacturer of genetically aligned formulations that create optimal cannabis experiences. Learn more at www.endodna.com.

###

July 6, 2021

Austin, Texas – The discovery of the genetic origins of Cannabinoid Hyperemesis Syndrome (CHS) is a major step forward in diagnosing and treating this previously enigmatic and poorly recognized, yet increasingly common condition triggered by high-THC consumption. Symptoms of CHS include intractable nausea, cyclic vomiting, abdominal pain, and hot bathing behavior in episodes that can last for several weeks and represent a grievous health and financial burden to its victims.  This study represents the largest patient cohort of CHS patients examined to date, and first to note associated mutations in genes affecting neurotransmitters, the endocannabinoid system (ECS), and the cytochrome P450 complex associated with cannabinoid metabolism.

“These important preliminary findings, contribute to the growing body of knowledge, stimulate additional investigation, help elucidate the pathophysiology of CHS and, ultimately, direct future treatment,” says chief investigator Ethan Russo, MD.

The scientific team was led by Dr. Russo, a world-renowned medical cannabis expert, and Len May, a leader in the field of endocannabinoid system (ECS) genomics. Dr. Russo is a board-certified neurologist, a psychopharmacology researcher, the CEO of CReDO Science, and a prolific author. Mr. May is the co-founder and CEO of Endocanna Health, a sought-after speaker and an author.

“CReDO Science is proud to have partnered with Endocanna Health in publishing this genetic marker discovery that highlights the risks and susceptibility its patients face,” said Dr. Russo. CHS is a relatively new phenomenon, and thus research is lacking in this area. Mr. May shares, “We are honored our discovery advances the science and understanding of this traumatic condition and that it is the first step in developing treatment and providing relief to patients.”

Through Endocanna Health, a CHS genomic test will be available to gastroenterologists and hospital emergency departments by the end of summer 2021. Mr. May explains, “Through genomic testing we can provide peace of mind to those consumers struggling with CHS.” Dr. Russo adds, “Screening patients for this condition will help obviate the need for repetitive hospitalizations, expensive and invasive diagnostics.”

The scientific team, which also includes naturopathic physician and cannabis scientist Chris Spooner, Ryan Leslie and Nishi Whiteley, is “focused on using this data to do a larger clinical study that will create an industry standard for CHS diagnostics,” said Mr. May.

Read the full article at Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation (liebertpub.com). 

CReDO Science LLC is a biopharma holding company that exists to solve problems of the human/animal ECS including developing optimized formulations from the Cannabis plant for better living. Learn more at www.credo-science.com.

Endocanna Health is the industry leader in endocannabinoid system genomic testing and, and the manufacturer of genetically aligned formulations that create optimal cannabis experiences. Learn more at www.endodna.com.